To What Extent Is Biotechnology Widening The Healthcare Gap Between Developed And Developing Nations

Imagine two children born on the same day — one in Oslo, Norway, and one in Bamako, Mali. Both carry the same rare genetic disorder. In Oslo, the child receives a gene therapy that corrects the underlying mutation before their second birthday. They grow up healthy, educated, and unburdened by the disease that could have defined their life. In Bamako, the same child never receives a diagnosis, let alone a treatment. The therapy exists. The science that produced it is real. But geography, economics, and global health architecture have conspired to ensure it never arrives. That gap — between what biotechnology can do and who it actually reaches — is one of the most urgent and underexamined injustices of our time.

Biotechnology has delivered miracles. mRNA vaccines, monoclonal antibody therapies, gene-editing treatments, precision oncology — these are not incremental improvements to medicine. They represent categorical leaps in what is biologically possible. But possibility and accessibility are very different things. And the uncomfortable truth is that the distribution of biotechnology’s benefits maps almost perfectly onto existing global wealth hierarchies. The countries that were already advantaged in healthcare are pulling further ahead, while the countries that were already struggling are falling further behind. The question isn’t whether biotechnology is widening the healthcare gap. It clearly is, in important ways. The question is how extensively, through what mechanisms, and whether anything can reverse the trajectory.

Defining the Healthcare Gap in the Biotechnology Era

The healthcare gap between developed and developing nations has always existed, but biotechnology is changing its character in important ways. Historically, the gap was primarily about basic infrastructure — clean water, sanitation, primary care access, essential medicines. Those gaps persist and remain catastrophic in their own right. But biotechnology is adding a new layer of disparity that operates at a higher level of medical sophistication.

We’re now in an era where the therapeutic frontier includes treatments priced at millions of dollars per patient, requiring cold-chain logistics, specialist clinical infrastructure, and genomic diagnostic capabilities that most high-income healthcare systems are still building. For low and middle-income countries, these aren’t barriers that require incremental improvement to overcome — they represent entirely different orders of magnitude of challenge. The gap isn’t widening on a linear scale. It’s widening exponentially, because the biotechnology frontier is advancing faster than developing nations’ capacity to access even its previous generation of innovations.

The Price Wall: Biotechnology’s Most Brutal Barrier

Let’s talk numbers, because they’re staggering. Zolgensma, a gene therapy for spinal muscular atrophy, carries a list price of approximately $2.1 million per dose. Hemgenix, a gene therapy for hemophilia B, was priced at $3.5 million — the most expensive drug ever approved at the time of its launch. Even more established biologics like monoclonal antibody cancer therapies routinely cost $100,000 to $500,000 per treatment course. These prices are challenging for the insurance systems of wealthy nations. For the healthcare budgets of low-income countries, they are simply incomprehensible.

Nigeria’s government healthcare expenditure per capita hovers around $20 annually. Ethiopia’s is lower. The idea that national health systems operating at these funding levels could integrate biotechnology therapeutics priced in the tens or hundreds of thousands of dollars is not a policy challenge — it’s an arithmetic impossibility. The pricing structures of biotechnology are designed around the ability-to-pay of wealthy-country payers. They are not incidentally inaccessible to developing nations — they are structurally inaccessible, built on economic assumptions that developing-world healthcare systems don’t come close to meeting.

Intellectual Property Systems Lock Out Generic Competition

When conventional drugs go off-patent, generic manufacturers can produce them at a fraction of the original cost, dramatically expanding access. This mechanism has been enormously important for global health — generic antiretrovirals transformed HIV treatment from a wealthy-world privilege into a broadly accessible therapy that has saved millions of lives in sub-Saharan Africa and beyond. Could the same happen with biotechnology products?

The answer is complicated and, in many respects, discouraging. Biologics — the protein-based drugs that dominate modern biotechnology — are vastly more complex to manufacture than small-molecule pharmaceuticals. Producing a biosimilar requires sophisticated fermentation technology, rigorous quality control, and regulatory validation that goes well beyond generic drug manufacturing. The barriers to biosimilar production are high even for sophisticated manufacturers in middle-income countries. And pharmaceutical companies have become increasingly skilled at extending intellectual property protection through patent thickets — layering multiple patents on different aspects of a biologic product to delay competition long after the original core patent expires. The generic pathway that democratized access to earlier generations of medicine works far less reliably for biotechnology.

Diagnostic Inequality: You Can’t Treat What You Can’t Diagnose

Biotechnology therapeutics are only relevant to patients who have received the diagnoses that make them applicable. Precision oncology works when you know which molecular mutations are driving a tumor. Gene therapy is relevant when you’ve identified which genetic variant is causing disease. Monoclonal antibody therapies depend on biomarker testing that guides patient selection. All of this requires diagnostic infrastructure — genomic sequencing, molecular pathology, specialized imaging, trained specialist physicians — that is severely limited across much of the developing world.

In practical terms, this means that patients in low-income countries who would theoretically benefit from biotechnology treatments are systematically excluded from accessing them not only by price but by the prior failure to identify their eligibility. They never make it through the diagnostic gateway that would establish their need. A biotechnology treatment that requires a genomic sequencing test for appropriate patient selection is, for most developing-world patients, effectively invisible — not because the treatment doesn’t apply to them, but because the system that would identify its applicability doesn’t exist in their healthcare environment.

Cold Chain and Infrastructure Requirements

Many biotechnology products have demanding storage and handling requirements that add another layer of access challenge. mRNA vaccines require ultra-cold storage temperatures. Cell therapies involve living biological materials with narrow viability windows. Some biologics require refrigeration throughout their entire supply chain journey from manufacturer to patient. In high-income countries, cold chain logistics are sophisticated, reliable, and largely taken for granted. In many developing nations, maintaining cold chain integrity across the distances and infrastructure conditions involved in reaching patients is a serious technical and logistical challenge.

This isn’t an unsolvable problem — the COVID-19 vaccine rollout demonstrated that cold chain logistics can be extended into low-resource settings with sufficient investment and coordination. But it requires investment and coordination that doesn’t happen automatically. And as biotechnology products become more biologically complex — as living cell therapies and gene therapies requiring specialized administration enter the pipeline — the infrastructure requirements escalate beyond what cold chain logistics alone can address.

The Brain Drain Effect: Losing the People Who Could Help

Developing nations face a particularly painful dynamic in healthcare biotechnology: the same educational investments they make in training scientists, physicians, and biotechnologists often result in those trained individuals emigrating to high-income countries where opportunities, salaries, and research resources are more abundant. This brain drain depletes the human capital that developing nations need most to build domestic biotechnology capacity and adapt global innovations to local contexts.

Sub-Saharan Africa has among the lowest physician-to-population ratios in the world, and a significant portion of its medically trained professionals practice in Europe or North America. The countries contributing to global biotechnology talent pipelines through their educational investments are not the countries capturing the returns on those investments. Building biotechnology access in developing nations requires retaining the people who could drive that access — and that requires creating the conditions that make staying competitive with leaving, which in turn requires the very resources that are currently absent.

COVID-19 Exposed the Access Gap With Devastating Clarity

The COVID-19 pandemic provided a real-time, globally visible demonstration of how biotechnology access inequality operates. mRNA vaccines — a triumph of biotechnology — were developed at unprecedented speed. But their initial distribution was almost entirely concentrated in high-income countries. The United States, United Kingdom, European Union, and a handful of other wealthy nations secured advance purchase agreements that locked up the majority of initial production capacity. By the time most African nations received meaningful vaccine supplies, the global conversation had moved on to boosters for populations that were already vaccinated.

The COVAX initiative, designed to ensure equitable global vaccine access, was chronically underfunded and consistently outcompeted by wealthy-country bilateral purchase agreements. Proposals for temporary intellectual property waivers that might have enabled faster vaccine production in developing-world manufacturing hubs were blocked or delayed by the same countries that most benefited from the biotechnology breakthrough. The pandemic didn’t create the biotechnology access gap — it illuminated it with brutal clarity for anyone willing to look honestly at what the data showed.

Africa’s Growing Biotechnology Ambitions

It would be wrong to portray developing nations as purely passive recipients — or non-recipients — of biotechnology’s benefits. Several emerging economies are actively building domestic biotechnology capabilities with genuine ambition and some genuine progress. South Africa, Kenya, Nigeria, and Egypt have developing biotechnology sectors. India, while technically a middle-income country, has become a global powerhouse in biosimilar manufacturing, producing affordable versions of biologic medicines that are reaching patients in lower-income markets globally. Brazil has significant pharmaceutical manufacturing capacity and has used compulsory licensing mechanisms to improve access to critical medicines.

China’s biotechnology sector has grown from a developing-world follower to a genuine global competitor in less than two decades, demonstrating that the development pathway is traversable with sufficient state investment and policy commitment. The lessons from China’s biotechnology development are being studied carefully by policymakers in other developing nations, even if the specific conditions that enabled China’s trajectory — scale, state capacity, industrial policy commitment — are not easily replicated elsewhere.

The Disease Priority Mismatch Problem

Here’s a dynamic that rarely gets the attention it deserves: the diseases that biotechnology research prioritizes are not the diseases that kill the most people in developing nations. Global biotechnology R&D investment is heavily concentrated in conditions that affect wealthy-world populations — certain cancers, autoimmune diseases, neurological conditions, metabolic disorders. Infectious diseases that remain major killers in low-income countries — malaria, tuberculosis, neglected tropical diseases — receive a fraction of the biotechnology R&D investment they would attract if funding followed disease burden rather than market potential.

This is a market failure in the most literal sense. The invisible hand of pharmaceutical investment is pointing in the opposite direction from where global health need is greatest. The result is a biotechnology pipeline extraordinarily rich in treatments for conditions affecting wealthy populations and persistently thin in innovations for conditions devastating developing-world communities. Organizations like the Medicines for Malaria Venture, Drugs for Neglected Diseases initiative, and the Global Alliance for TB Drug Development exist precisely to compensate for this market failure through public and philanthropic funding — but their resources are modest compared to the commercial R&D budgets flowing toward wealthy-market conditions.

Compulsory Licensing: A Tool That Exists But Faces Resistance

The TRIPS Agreement — the international intellectual property framework governing pharmaceutical patents — includes provisions allowing countries to issue compulsory licenses for medicines in public health emergencies, effectively allowing domestic production or importation of generic versions of patented drugs without patent holder consent. This mechanism has been used successfully — Brazil and Thailand have issued compulsory licenses for HIV antiretrovirals, and South Africa has used similar provisions.

But compulsory licensing for biotechnology products faces additional complications. Manufacturing a biosimilar version of a complex biologic requires capabilities that most low-income country manufacturers don’t possess. You can compulsorily license a patent, but you can’t compulsorily license the manufacturing knowledge, the fermentation expertise, and the quality control systems needed to actually produce the product. Compulsory licensing is a more powerful tool for small-molecule drugs than for complex biologics, which is yet another way biotechnology’s characteristics specifically disadvantage developing-world access efforts.

Technology Transfer: Promises Made and Broken

International agreements and development commitments frequently include provisions for technology transfer — sharing the manufacturing knowledge and processes that enable developing-country producers to make medicines independently. The reality of technology transfer in biotechnology has been deeply disappointing. Pharmaceutical companies have strong commercial incentives to minimize the completeness of technology transfers, protecting proprietary manufacturing processes and quality systems even while nominally complying with transfer agreements.

The WHO’s mRNA Technology Transfer Programme, launched after COVID-19 to build mRNA vaccine manufacturing capacity in developing nations, represents a more serious attempt at genuine technology transfer — sharing actual process knowledge, providing hands-on technical training, and supporting regulatory capacity building. Its progress has been slower than advocates hoped, but it represents a model more likely to produce real capability development than previous token transfer arrangements. Whether it succeeds at meaningful scale will be an important indicator of whether the global community can build more equitable biotechnology access architecture.

Philanthropic Efforts: Essential But Insufficient

The Gates Foundation, Wellcome Trust, and numerous other philanthropic organizations have made substantial investments in improving biotechnology access for developing nations — funding vaccine development for neglected diseases, supporting biosimilar manufacturing capacity, underwriting access programs for HIV and tuberculosis biologics. These contributions are genuinely significant and have saved lives that market mechanisms alone would have abandoned.

But philanthropy is an unreliable foundation for systemic change. Foundation priorities shift. Funding cycles create uncertainty. And the scale of philanthropic investment, however impressive in absolute terms, remains small relative to the commercial biotechnology economy it’s trying to counterbalance. Treating philanthropic intervention as a primary strategy for biotechnology equity is like treating food banks as a primary strategy for food security — valuable in addressing immediate need, but inadequate as a response to structural injustice.

What Would Actually Make a Difference

Reversing biotechnology’s contribution to healthcare inequality requires interventions at multiple levels simultaneously. Delinkage — separating the cost of R&D from the price of final products — is one of the most discussed structural reforms. Under this model, public funding covers R&D costs upfront, allowing products to be priced at manufacturing cost rather than at levels designed to recoup R&D investment through sales. This is not a radical idea — it’s how most basic science is already funded, and elements of it were applied in COVID vaccine development.

Strengthening developing-world regulatory agencies — so they can efficiently evaluate and approve biotechnology products rather than simply deferring to FDA or EMA approvals — would accelerate domestic manufacturing authorization. Expanding the TRIPS flexibilities available to low-income countries, and ensuring that wealthy nations don’t use bilateral trade agreements to claw back those flexibilities, would improve the compulsory licensing toolkit. And genuinely investing in manufacturing capacity in developing regions — not token technology transfer, but real capability building — would create the production infrastructure that makes access possible independent of wealthy-country supply chain decisions.

The Equity Argument Is Also a Pragmatic One

Some people frame biotechnology access equity purely as a moral argument — and it is a moral argument, a compelling one. But it’s also a pragmatic one. The COVID-19 pandemic demonstrated with devastating clarity that infectious diseases don’t respect national borders. Vaccine inequity didn’t just harm unvaccinated populations — it extended the pandemic globally, increased the probability of new variant emergence, and ultimately cost wealthy nations time, lives, and economic productivity. Global health security depends on global health equity in ways that even narrowly self-interested actors should be able to recognize.

A world where biotechnology’s benefits are concentrated in wealthy nations while infectious diseases, antimicrobial resistance, and pandemic risk continue to emerge from undervaccinated, undertreated populations is not a stable world. Building biotechnology access in developing nations isn’t charity extended from abundance — it’s investment in the shared biological infrastructure of global health security.

Conclusion

Biotechnology is widening the healthcare gap between developed and developing nations — not marginally, not incidentally, but substantially and through mechanisms that are structural rather than accidental. The pricing architecture of biologic medicines, the intellectual property systems that delay generic competition, the diagnostic infrastructure requirements that precede treatment access, the disease priority mismatches in global R&D investment, and the cold chain and specialist skill requirements of advanced therapies all combine to ensure that the most powerful medical tools of our era are overwhelmingly concentrated in the hands of those who already had the best healthcare.

That’s not an inevitable feature of biotechnology — it’s a choice embedded in the policies, pricing systems, and international agreements that govern how biotechnology develops and distributes its benefits. Different choices are possible, and some are already being made in partial and imperfect ways. Whether we make them fully, urgently, and at scale is one of the defining global health justice questions of the coming decade. The science of biotechnology has expanded what’s medically possible for humanity. The politics and economics of biotechnology access will determine whether that expanded possibility reaches all of humanity — or just the wealthiest fraction of it.

FAQs

See More

Jude

Henry Jude writes about biotechnology and housing technology, focusing on the latest trends. He has 15 years of experience reporting on and analyzing advances in these fields. Holding both a BSc and an MSc in Biotechnology, he uses his scientific training to explain complex ideas clearly and show how new technologies can be applied in real life.